Biology subjects

Byrne, A. T.

Publications and source records attributed to Byrne, A. T..

4 recordsLinked to original sources

bioRxiv2026

The development of coarse and fine feature tuning in infant visual cortex

Objects can be recognized from visual features at multiple spatial scales, from coarse global shape to fine local detail. How infant visual cortex encodes these features across the visual hierarchy, however, remains unknown. We combined awake infant fMRI with developmentally inspired deep neural networks (DNNs) trained and tested with different levels of image blur to probe cortical tuning to coarse and fine visual features. V1 showed mature tuning to coarse and fine features by 2 months. In contrast, infant extrastriate cortex (V2-V4) followed a protracted developmental trajectory and was biased toward coarse object features relative to adults. This relative bias persisted at 9 months and was not readily explained by developing acuity. The sustained coarse-feature bias contrasted with DNNs, in which low-spatial-frequency representations took longest to converge with visual cortex during training, revealing distinct developmental biases in object-feature tuning in biological and artificial visual systems.

neuroscience↗

bioRxiv2025

Distinct tumor immune microenvironmental (TIME) landscapes drive divergent immunotherapy responses in glioblastoma

BackgroundImmunotherapies have improved outcomes in many cancers but show limited efficacy in glioblastoma (GBM). This study aimed to determine whether immunotherapy could be tailored to GBM by functional subtyping of vascular-immune landscapes. MethodsWe employed single-cell RNA sequencing, multiplex immunohistochemistry to characterize three distinct TIME subtypes in human and murine GBMs. We evaluated responses to combination of anti-angiogenic immunomodulating therapies (CD40 Ag, anti-PDL1, PI3K{gamma}/{delta} inhibition) in orthotopic syngeneic GBM mouse models. ResultsWe identified three distinct functional TIME subtypes with unique vascular-immune landscapes in human and murine GBM: TIME-low (immune-low/deserted, leaky vasculature), TIME-med (intermediate immune-infiltration, angiogenic), and TIME-high (heavily infiltrated with immunosuppressive myeloid cells and dysfunctional T cells). Representative mouse models of TIME-GBMs responded in subtype specific ways to anti-angiogenic immunomodulating therapies. TIME-low GBMs enhanced T-cell activity but relapsed due to emerging myeloid immunosuppression, concomitant with mesenchymal transition. TIME-med displayed the most immune-activated, yet angiogenic phenotype, and showed overall good responses to various anti-angiogenic immunomodulating therapies. TIME-high GBMs were mostly non-responsive but improved when the myeloid-cell PI3K{gamma} was targeted. However, CD40 agonist treatment, expected to enhance APC function, unexpectedly worsened survival by promoting angiogenesis and heightening immunosuppression, leading to dysfunctional T cells and reduced NK cell recruitment, and subsequent enhanced tumor propagation. ConclusionsOur study reveals three GBM TIME subtypes with distinct vascular-immune landscapes that require tailored therapies. TIME-med tumors are predicted to respond best to immunotherapies, TIME-low tumors show transient effects with anti-angiogenic immunomodulating therapies, while TIME-high tumors, due to their profound immunosuppression, can even have worse outcomes. Key pointsO_LIThree TIME subtypes were identified in GBM with distinct vascular-immune landscapes C_LIO_LITIME subtypes show divergent immunotherapy responses C_LIO_LITIME classification supports personalized treatment strategy for GBM immunotherapy C_LI Importance of the StudyThis study advances glioblastoma immunotherapy by providing the first comprehensive single-cell characterization of TIME subtypes, moving beyond bulk RNA-sequencing to reveal detailed functional states of immune cells. We establish clinically relevant murine models that recapitulate human TIME subtypes, enabling preclinical testing of TIME-targeted therapies. Our findings identify TIME-low GBM as immune deserted and TIME-med tumors as the most immunotherapy-responsive subtype that should be prioritized for clinical selection. We found that high immune infiltration correlates with non-responsiveness and even unexpected detrimental effects with CD40 agonist treatment in TIME-high tumors--critical information given ongoing clinical trials. Identifying distinct immunosuppressive mechanisms across TIME subtypes and differential treatment responses provides a framework for personalized immunotherapy selection. The immediate translational impact of this work highlights the importance of TIME classification for treatment stratification and the urgent need to consider TIME status in clinical trial design, potentially explaining variable patient responses in previous GBM immunotherapy trials.

cancer biology↗

bioRxiv2025

DREAMER-S: Deep leaRning-Enabled Attention-based Multiple-instance approaches with Explainable Representations for Spatial Biology

Identifying image features that associate strongly with diagnostic or prognostic classes in large-scale, multi-channel spatial imaging is challenging without pixel-level annotations. We present DREAMER-S, an attention-based multiple-instance learning (MIL) framework that, using only image- or slide-level labels, learns spatial features within 3D imaging hypercubes that are most informative for downstream classification. We demonstrate DREAMER-S on Quantum Cascade Laser infrared (QCL-IR) tissue imaging, where attention weights are rendered spatially to highlight class-relevant spectral instances without manual annotation. Because the MIL attention layer assigns interpretable importances to spatial instances, the method is broadly transferable to spatial-biology applications that require instance-level filtering to focus towards salient regions of interest in high-content datasets. We further evaluate DREAMER-S on a chemotherapy-response task in a colorectal cancer patient-derived xenograft (PDX) model. After tuning, DREAMER-S separated spectral instances from a chemo-sensitive PDX (CRC0344) and a less responsive PDX (CRC0076) with an F1 score of [~]0.95. To validate explainability, we linked model saliency to cellular physiology, observing that, (i) unsupervised UMAP embeddings of high-attention spectra stratified samples by treatment (chemotherapy, apoptosis sensitizer, combination, vehicle), and (ii) selected spectral markers correlated with pro-apoptotic proteins measured independently in the same PDX system. Together, these results support a mechanistic link between spectral signals and apoptosis pathways and position DREAMER-S as an efficient, interpretable approach for analysing high-content spatial-biology imaging datasets.

bioinformatics↗

bioRxiv2023

Identification of inter- and intra-tumoral molecular phenotypes steering temozolomide resistance in patient-derived glioblastoma cells.

BackgroundRadiation therapy and chemotherapy using Temozolomide are the standard adjuvant treatments for patients with glioblastoma. Despite maximal treatment prognosis is still poor largely due to the emergence of Temozolomide resistance. This resistance is closely linked to the widely recognized inter- and intra-tumoral heterogeneity in glioblastoma, although the underlying mechanisms are not yet fully understood. This study aims to investigate the diverse molecular mechanisms involved in temozolomide resistance. MethodsTo induce temozolomide resistance, we subjected 21 patient-derived glioblastoma cell cultures to Temozolomide treatment for a period of up to 90 days. Prior to treatment, the cells molecular characteristics were analyzed using bulk RNA sequencing. Additionally, we performed single-cell sequencing on four of the cell cultures to track the evolution of temozolomide resistance. ResultsThe induced temozolomide resistance was associated with two distinct phenotypic behaviors, classified as "adaptive" (ADA) or "non-adaptive" (N-ADA) to temozolomide. The ADA phenotype displayed neurodevelopmental and metabolic gene signatures, whereas the N-ADA phenotype expressed genes related to cell cycle regulation, DNA repair, and protein synthesis. Single-cell RNA sequencing revealed that in ADA cell cultures, one or more subpopulations emerged as dominant in the resistant samples, whereas N-ADA cell cultures remained relatively stable. ConclusionsThe adaptability and heterogeneity of glioblastoma cells play pivotal roles in temozolomide treatment and contribute to the tumors ability to survive. Depending on the tumors adaptability potential, subpopulations with acquired resistance mechanisms may arise. Further research is necessary to deepen our understanding of these mechanisms and develop strategies to overcome them.

cancer biology↗